Aerie Pharma (AERI) Enters $50M Equity Offering Sales Agreement

Aerie Pharma (AERI) Announces $50M Common Stock Offering

Aerie Pharmaceuticals, Inc. (Nasdaq: AERI) announced that it has commenced a registered underwritten public offering of $50 million of shares of its common stock.

Cantor Fitzgerald & Co. is acting as the sole underwriter for the offering.

Aerie intends to use the net proceeds of the offering for general corporate purposes, including the complete... More

Aerie Pharma (AERI) PT Lifted to $50 at Stifel on Strong Roclatan Results

Stifel analyst Annabel Samimy reiterated a Buy rating and boosted his price target on Aerie Pharma (NASDAQ: AERI) to $50.00 (from $40.00) after the company reported unequivocally positive results from its Phase 3 Roclatan MERCURY-1 study. This 90-day primary efficacy readout demonstrated statistically significant IOP-lowering of Roclatan over... More

Aerie Pharma (AERI) PT Raised to $50 at Cantor Fitzgerald

Cantor Fitzgerald analyst Elemer Piros reiterated a Buy rating and raised his price target on Aerie Pharma (NASDAQ: AERI) to 50.00 (from $44.00) after the company reported "impeccable" Phase 3 results with its combination eye drop Roclatan from a 700-patient+ trial.

Piros commented, "When comparing the... More

RBC Lifts PT on Aerie Pharma (AERI) to $55 Following Roclatan Phase 3 Results

RBC Capital boosts its price target on Outperform-rated Aerie Pharmaceuticals (Nasdaq: AERI) from $51 to $55 after the company announced positive Roclatan phase 3 data.

The firm commented, The second Phase 3 is similar in design so it should work as well making Roclatan approvable, a... More

Aerie Pharma (AERI) PT Raised to $52 at Needham & Company as Roclatan Knocks It Out of the Park

Needham & Company analyst Serge Belanger reiterated a Buy rating and boosted his price target on Aerie Pharma (NASDAQ: AERI) to $52.00 (from $45.00) after the company reported positive results from MERCURY-1, the first of two ph 3 trials evaluating Roclatan (fixed-dose combo of Rhopressa and latanoprost)... More

Aerie (AERI) September volatility at 190 into 'successful' efficacy results of Phase 3 Roclatan trial

Aerie Pharma (NASDAQ: AERI) is recently up $12.17 to $33.30 in the premarket after reporting 'successful' efficacy results of Phase 3 Roclatan trial. September call option implied volatility is at 190, October is at 200; compared to its 52-week range of 63 to 274.

Aerie Pharma (AERI) Announces Statistically Significant Data from Roclatan Phase 3 Mercury 1 Trial

Aerie Pharmaceuticals, Inc. (Nasdaq: AERI) reported the successful 90-day primary efficacy results of its 12-month Phase 3 Mercury 1 clinical trial for its fixed-dose combination product candidate, Roclatan. The study achieved its primary efficacy endpoint demonstrating statistical superiority over each of its components, including Aerie product candidate Rhopressa (netarsudil ophthalmic solution) 0.02%, and market leading prostaglandin analogue (PGA) latanoprost, all of which were dosed once daily in the evening. The study evaluated patients with maximum baseline intraocular pressures (IOPs) ranging from above 20 to below 36 mmHg (millimeters of mercury). The IOP-lowering effect of RoclatanTM was 1 to 3 mmHg greater than... More